<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04045171</url>
  </required_header>
  <id_info>
    <org_study_id>XY3-IIT-TAC1905A01</org_study_id>
    <nct_id>NCT04045171</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome</brief_title>
  <acronym>PISTONS</acronym>
  <official_title>Population Pharmacokinetics of Tacrolimus for Optimal Dose in Patients With Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZhuZhou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Chenzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use a multi-center, prospective design, with a &quot;Real World Study&quot; model, to
      include 200 patients with nephrotic syndrome. based on the Population Pharmacokinetics (PPK)
      model, it will study genotype and clinical factors in patients with nephrotic syndrome, to
      explore the Pharmacokinetics/ Pharmacodynamics (PK/PD) relationship of Tacrolimus in patients
      with nephrotic syndrome, and develop an optimal medication regimen.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change of plasma concentration of Tacrolimus</measure>
    <time_frame>at 0hour，2hours，4hours，6hours，9hours，12hours after oral administration</time_frame>
    <description>Study the plasma concentration of Tacrolimus in patients with nephrotic syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotypes as measured by next generation sequencing</measure>
    <time_frame>one week</time_frame>
    <description>Genotypes as measured by next generation sequencing</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <condition>Tacrolimus</condition>
  <condition>Pharmacokinetics</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biospecific nonspecimen specimen will be collected for the PK analysis of Tacrolimus and the
      gene information of Cytochrome P450 3A (CYP3A)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Nephrotic Syndrome are suit for use of Tacrolimus.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  （1）Patients with Nephrotic Syndrome：

               1. Proteinuria greater than 3.5 g/24 hour

               2. Serum albumin &lt;30 g/l

               3. Clinical evidence of peripheral oedema

               4. Hyperlipidemia 1) and 2) are necessary for diagnosis.

          -  （2）18—75years old（include 75），gender is not limited；

          -  （3）Voluntary signing informed consent。

        Exclusion Criteria:

          -  （1）Secondary nephrotic syndrome；

          -  （2）Allergic to Tacrolimus or other unsuitable use of Tacrolimus；

          -  （3）With other immunosuppressive agents such as cyclosporin A, cyclophosphamide,
             mycophenolate mofetil, leflunomide, tripterygium wilfordii (hormone is not
             restricted)；

          -  （4）Severe liver dysfunction (transaminase &gt; 3 ULN, or bilirubin &gt; 3 ULN)；

          -  （5）Severe renal insufficiency（eGFR＜30 ml/min/1.73m2）

          -  （6）Joined other clinical trials within 1 month；

          -  （7）Missing clinical data；

          -  （8）Pregnancy, lactation or planning for pregnancy within 12 months；

          -  （9）Researchers believe that patients who are not suitable for this clinical trial。
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZHIJUN HUANG, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ZHIJUN HUANG, Dr.</last_name>
    <phone>073188618339</phone>
    <email>huangzj@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BIN YI, Dr.</last_name>
    <phone>073188618210</phone>
    <email>yibin_yb@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Lu T, Zhu X, Xu S, Zhao M, Huang X, Wang Z, Zhao L. Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome. Pharm Res. 2019 Feb 4;36(3):45. doi: 10.1007/s11095-019-2579-6.</citation>
    <PMID>30719576</PMID>
  </reference>
  <reference>
    <citation>Hao GX, Huang X, Zhang DF, Zheng Y, Shi HY, Li Y, Jacqz-Aigrain E, Zhao W. Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. Br J Clin Pharmacol. 2018 Aug;84(8):1748-1756. doi: 10.1111/bcp.13605. Epub 2018 May 22.</citation>
    <PMID>29637588</PMID>
  </reference>
  <reference>
    <citation>Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int. 2012 Oct;82(8):840-56. doi: 10.1038/ki.2012.280. Epub 2012 Aug 15. Review.</citation>
    <PMID>22895519</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Population Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We welcomes researchers interested in collaboration. We request a short research proposal including information on the background, research questions and methods, timetable and budget, and authorship. For more information please contact the principal investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

